New hope for rare artery disease? small trial tests upadacitinib
NCT ID NCT07500467
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed study tested the drug upadacitinib in 12 people with refractory Takayasu arteritis, a rare autoimmune disease that inflames the body's largest artery. The goal was to see if the drug could help patients who haven't responded to standard treatments achieve remission within 24 weeks. The trial focused on safety and how many patients experienced partial or complete remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat Takayasu arteritis.
What could go wrong
This is a very small, early-phase study with only 12 participants, so results may not apply widely. The drug also carries risks like infection and side effects common to JAK inhibitors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- LAVA-FLOW Study: Better PET Scans for Vasculitis NCT07628075
- EACVI-INFLAME Heart Imaging Study (NCT07077304)
- Stopping Biologics in Takayasu Arteritis Study | NCT07491913
- Secukinumab for Takayasu Arteritis Trial (NCT07477795)
- Takayasu Arteritis Care Study | NCT07351422
- VCRC Tissue Biorepository Study (NCT02967068)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, China